ClinicalJapanese Pharmaceutical Company Kowa claims Ivermectin exerts “antiviral effect”...

Japanese Pharmaceutical Company Kowa claims Ivermectin exerts “antiviral effect” against COVID

-

Japnese pharmaceutical and drug development company Kowa commented that the anti-parasite drug ivermectin demonstrates an “anti-viral” effect against the Omicron variant of COVID-19 in a joint non-clinical research

The company, in collaboration with Kitasato University since the start of the pandemic, didn’t mention any further details.

There is ongoing clinical research on the effect of ivermectin on COVID-19 patients and the subject has generated much controversy.

Noticeable vaccine cynic Joe Rogan, whose episodes on Spotify and other podcasting platforms have incited opposition by musicians Joni Mitchell and Neil Young, has long incited debate with his perspectives on the pandemic, government orders, and COVID-19 immunizations. Rogan claims that he has chosen to use Ivermectin over getting vaccinated. 

Japan has banned the marketing of Ivermectin as a cure for COVID-19. The FDA, the World Health Organization, the EU drug controller, and Merck (MRK.N), which manufactures the medication, have cautioned against its use due to an absence of any science-based proof that it has a medicinal impact.

In September 2021, the FDA website mentioned the developing interest in the medication for forestalling or treating COVID-19 in people yet said it had gotten different new of patients who had needed clinical consideration, including hospitalization, after self-medicating with it.

The utilization of ivermectin to treat COVID-19 is right now being researched in a UK preliminary trial by the University of Oxford. The researchers mentioned that their study is ongoing and refused to comment further

Numerous potential COVID-19 medicines that showed guarantee in test tubes failed to prove their efficacy in COVID-19 patients once considered in clinical trials, including the antimalarial hydroxychloroquine promoted by Donald Trump.

Life Sciences Voice Logo mobile
+ posts

Latest news

FDA Delays Biohaven’s Approval Decision for Rare Disease Drug Troriluzole

The U.S. Food and Drug Administration (FDA) has postponed its decision on Biohaven Pharmaceuticals’ lead drug candidate, troriluzole, a...

Pathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered Cancer Drug Development

Pathos AI, a clinical-stage biotech company leveraging artificial intelligence to revolutionize cancer treatment, has announced the successful close of...

Life Sciences Voice Top Five Newsletter

Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you